Moderna Just Proved mRNA Isn't a One-Hit Wonder
The FDA just approved the first-ever mRNA flu vaccine, and it's not just about the flu. Moderna's mFlusiva could reshape how we make seasonal vaccines, ditch the decades-old egg-based process, and prove mRNA is a platform, not a pandemic fluke.
Six Billion Eggs Have a Problem
Every year, flu vaccine manufacturers crack open hundreds of millions of fertilized chicken eggs, inject influenza virus into them, wait for the virus to grow, and harvest the result. The whole process takes about six months. And it starts so early that scientists have to guess which flu strains will be circulating half a year later.
Sometimes they guess wrong. Sometimes the virus mutates while growing inside the eggs, subtly changing the vaccine so it no longer matches what's actually making people sick. It's a little like printing next year's calendar based on last year's weather forecast.
On August 5, the FDA approved a vaccine that sidesteps that entire mess. Moderna's mFlusiva is the first-ever mRNA-based seasonal flu shot to reach the U.S. market. And it matters far beyond influenza.
What the FDA Actually Approved
mFlusiva is cleared for adults 50 years and older, covering both influenza A and B strains. But there's a regulatory wrinkle worth understanding.
For people aged 50 to 64, the vaccine received traditional approval, meaning the FDA saw enough clinical evidence to give it a full green light. For those 65 and older, it got accelerated approval, which is based on immune-response data rather than fully confirmed real-world benefit. Moderna will need to run follow-up studies proving the vaccine works as expected in that older group, or the approval could be pulled.
Think of it like a conditional job offer: you got the gig, but there's a probationary period.
The Numbers: Modest but Meaningful
Let's talk about what mFlusiva actually proved in its pivotal Phase 3 trial. The vaccine wasn't tested against a placebo (that would be unethical when effective flu shots already exist). Instead, it went head-to-head against a standard-dose flu vaccine that's already on the market.
The headline number: 26.6% relative vaccine efficacy over the comparator. In practical terms, 2.0% of mRNA recipients got flu-like illness, compared to 2.8% in the standard-vaccine group. That gap might sound small, but across millions of vaccinations it adds up fast.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
